Literature DB >> 11282207

Immunogenicity of the E1E2 proteins of hepatitis C virus expressed by recombinant adenoviruses.

Y R Seong1, S Choi, J S Lim, C H Lee, C K Lee, D S Im.   

Abstract

The E1 and E2 proteins of hepatitis C virus (HCV) are believed to be the viral envelope glycoproteins that are major candidate antigens for HCV vaccine development. We reported previously that the replication-competent recombinant adenovirus encoding core-E1-E2 genes of HCV (Ad/HCV) produces serologically reactive E1 and E2 proteins forming a heterodimer in substantial amounts. Here, we examined immunogenicity of the E1E2 proteins copurified from HeLa cells infected with Ad/HCV virus in mice. Furthermore, we constructed a replication-defective recombinant adenovirus encoding the core-E1-E2 genes of HCV (Ad.CMV.HCV) and examined immunogenicity of the virus in mice. The mice immunized intraperitoneally with the copurified E1E2 proteins induced mainly antibodies to E2, but not to E1 by Western blot analysis. The sera of mice immunized with the E1E2 inhibited the binding of E2 protein to the major extracellular loop of human CD81. E2-specific cytotoxic T cells (CTLs), but not antibodies to the E1E2 antigens were induced in the mice intramuscularly immunized with Ad.CMV.HCV virus. When immunized with both Ad.CMV.HCV virus and the E1E2, mice elicited E2-specific CTLs and antibodies to the E1E2 antigens. The results suggest that immunization of Ad.CMV.HCV virus combined with E2 protein is an effective modality to induce humoral as well as cellular immune response to E2 antigen.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11282207     DOI: 10.1016/s0264-410x(00)00534-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques.

Authors:  Stefania Capone; Annalisa Meola; Bruno Bruni Ercole; Alessandra Vitelli; Monica Pezzanera; Lionello Ruggeri; Mary Ellen Davies; Rosalba Tafi; Claudia Santini; Alessandra Luzzago; Tong-Ming Fu; Andrew Bett; Stefano Colloca; Riccardo Cortese; Alfredo Nicosia; Antonella Folgori
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

2.  Generation of hepatitis C virus-like particles by use of a recombinant vesicular stomatitis virus vector.

Authors:  Heather J Ezelle; Dubravka Markovic; Glen N Barber
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

3.  Protective cellular immune response against hepatitis C virus elicited by chimeric protein formulations in BALB/c mice.

Authors:  Santa Olivera; Angel Perez; Viviana Falcon; Dioslaida Urquiza; Dagmara Pichardo; Gillian Martinez-Donato
Journal:  Arch Virol       Date:  2020-02-03       Impact factor: 2.574

4.  Baculovirus vectors elicit antigen-specific immune responses in mice.

Authors:  Andrea Facciabene; Luigi Aurisicchio; Nicola La Monica
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

5.  Identification and characterization of broadly neutralizing human monoclonal antibodies directed against the E2 envelope glycoprotein of hepatitis C virus.

Authors:  Teresa J Broering; Kerry A Garrity; Naomi K Boatright; Susan E Sloan; Frantisek Sandor; William D Thomas; Gyongyi Szabo; Robert W Finberg; Donna M Ambrosino; Gregory J Babcock
Journal:  J Virol       Date:  2009-09-16       Impact factor: 5.103

6.  Adenovirus-mediated interleukin-12 gene transfer combined with cytosine deaminase followed by 5-fluorocytosine treatment exerts potent antitumor activity in Renca tumor-bearing mice.

Authors:  Kyung-Sun Hwang; Won-Kyung Cho; Jinsang Yoo; Hwan-Jung Yun; Samyong Kim; Dong-Soo Im
Journal:  BMC Cancer       Date:  2005-05-24       Impact factor: 4.430

7.  Evaluation of a recombinant measles virus expressing hepatitis C virus envelope proteins by infection of human PBL-NOD/Scid/Jak3null mouse.

Authors:  Masaaki Satoh; Makoto Saito; Kohsuke Tanaka; Sumako Iwanaga; Salem Nagla Elwy Salem Ali; Takahiro Seki; Seiji Okada; Michinori Kohara; Shinji Harada; Chieko Kai; Kyoko Tsukiyama-Kohara
Journal:  Comp Immunol Microbiol Infect Dis       Date:  2010-03-17       Impact factor: 2.268

Review 8.  Novel Concepts for HIV Vaccine Vector Design.

Authors:  Quazim A Alayo; Nicholas M Provine; Pablo Penaloza-MacMaster
Journal:  mSphere       Date:  2017-12-06       Impact factor: 4.389

Review 9.  Adenoviruses as vaccine vectors.

Authors:  Nia Tatsis; Hildegund C J Ertl
Journal:  Mol Ther       Date:  2004-10       Impact factor: 11.454

Review 10.  Understanding Post Entry Sorting of Adenovirus Capsids; A Chance to Change Vaccine Vector Properties.

Authors:  Coralie F Daussy; Noémie Pied; Harald Wodrich
Journal:  Viruses       Date:  2021-06-24       Impact factor: 5.048

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.